Previous Close | 4.4300 |
Open | 4.4300 |
Bid | 4.2200 x 2900 |
Ask | 4.4000 x 900 |
Day's Range | 4.1800 - 4.4300 |
52 Week Range | 1.3300 - 5.4000 |
Volume | 465,112 |
Avg. Volume | 637,998 |
Market Cap | 109.783M |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4510 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.75 |
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at B. Riley's Inaugural Oncology Investor Conference to be held January 20-21, 2021.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.